当前位置：首页 > 文献互助 > 互助详情

Burden of Atopic Dermatitis in China and Its Provinces, 1990–2021: A Global Burden of Disease 2021 Analysis复制

用户lCrXlT2ANPjQ 1小时前 5 10 求助中 帖子自动结束时间: 2026-04-27 11:16:27

1. 文件大小不能超过300M, 允许上传文档或压缩包等

2. 请确保上传文献的真实性、完整性，不得对原文做任何修改

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1111/ijd.70085复制

文献链接: https://onlinelibrary.wiley.com/doi/10.1111/ijd.70085复制

其他信息:

出版社: Wiley
作者: Weijia Zhao; Pengpeng Ye; Haihui Yang; Yunqing Yang; Shunmin Zhu; Hajanirina Jade Cheung; Bin Yang; Yunsheng Liang; Changchang Li
全文下载地址: https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.70085

上一篇：Ahmed MS et al. Identification of FDA-approved drugs that induce heart regeneration in mammals.

下一篇：Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials

互助时间线

2026-04-22 11:16:27 [发起求助]

最新发布的求助

Yanxiao Di’naer decoction attenuates metabolic dysfunction-associated steatohepatitis through the regulation of gut microbiota and the metabolism of bile acid 14分钟前
Tangeretin formulated in a self-nano-emulsifying drug-delivery system (SNEDDS) alleviates symptoms of rheumatoid arthritis by antagonizing M1 macrophages polarization 45分钟前
Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets 50分钟前
Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets 53分钟前
Updates on the Perioperative Management of Resectable Non–Small Cell Lung Cancer 1小时前
HSR26-260: Comparative Efficacy and Safety of Second-Line Therapies in Relapsed Small-Cell Lung Cancer: A Systematic Review and Pooled Analysis 1小时前
Model-based dose selection for phase 3 trials of the selective P2X3 antagonist camlipixant in refractory chronic cough 1小时前
Antibody–Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond 1小时前
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial 1小时前
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial 1小时前
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 1小时前
Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials 1小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com